IGF1R and lung carcinoma: Consequently, therapeutic strategies targeting the IGF axis, such as IGF-1R inhibition by OSI-906 [81], brigatinib [86], and osimertinib [76], have shown promising efficacy and could have an important anti-tumoral potential in lung cancer.